Nasdaq determines that transcode therapeutics has regained compliance with continued listing requirements

Boston, june 10, 2024 (globe newswire) -- transcode therapeutics, inc. (nasdaq: rnaz), (the “company”), an rna oncology company committed to more effectively treating cancer using rna therapeutics, today announced that it has received notice from the nasdaq stock market llc (nasdaq) that the company has regained compliance with all applicable nasdaq listing standards. as a result, the company's stock will remain listed and traded on the nasdaq stock market.
NDAQ Ratings Summary
NDAQ Quant Ranking